Paradigm Immunotherapeutics

Paradigm Immunotherapeutics is a pre-clinical stage biotechnology company focused on developing a novel class of antigen-specific immunotherapies for autoimmune diseases and severe allergies. Spun out from the University of Michigan, the company utilizes a proprietary nanoemulsion platform designed to induce immune tolerance rather than broad immunosuppression. By delivering specific antigens within a specialized nanoemulsion, the technology aims to recalibrate the immune system to recognize these antigens as non-threatening, potentially providing long-lasting disease modification. The company's primary research programs target high-need areas such as Type 1 Diabetes, food allergies, and Multiple Sclerosis. Paradigm's approach represents a significant shift in treating immune-mediated conditions by focusing on the underlying cause of the immune dysfunction.